This site is intended for U.S. health care professionals.
This site is intended for U.S. health care professionals.

Organon is committed to making a difference by supporting the adoption of biosimilars across the health care system.

See How We're Different
Why Biosimilars Matter Video
Why Biosimilars Matter Video
Biosimilar Formulary Review - Clinical Parameters
At Organon Biosimilars, we aspire to go above and beyond to deliver a biosimilar adoption experience that exceeds your expectations by collaborating with established manufacturers, educating providers, and offering patient resources about why biosimilars matter.
What generics were to the US health care system in the 20th century is what biosimilars have the potential to become in the 21st century: a paradigm shift that may deliver more competition, increase treatment options, and help lower costs to the health care system.1,2,3
Delivering biosimilars isn’t just a purpose—it’s a cause. We’re committed to improving access by making more biosimilars available. Learn about the difference biosimilars could make to the health care system.

References: 1. Stark A. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan. US Food and Drug Administration (FDA). July 18, 2018. Accessed March 2, 2023. https://www.fda.gov/news-events/press-announcements/remarks-fda-commissioner-scott-gottlieb-md-prepared-delivery-brookings-institution-release-fdas 2. US Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. July 2018. Accessed March 2, 2023. https://www.fda.gov/media/114574/download 3. Biosimilar and interchangeable biologics: more treatment choices. US Food and Drug Administration. Updated October 12, 2021. Accessed March 16, 2023. https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices